MEDFORD, NY and SAN JOSE, CA -- (MARKET WIRE) -- May 08, 2007 -- Chembio Diagnostics, Inc. (OTCBB: CEMI) and Avago Technologies have signed a letter of intent (LOI) to enter into a collaboration that will integrate Chembio’s patented DPP technology and assay development expertise with Avago’s opto-electronic measurement technology. The parties intend that this collaboration will facilitate the development of rapid point of care diagnostic systems which are technically superior to currently marketed devices. The initial disease focus will be various HIV test prototypes employing Chembio’s DPP technology that would be developed with third parties pursuant to their specifications. Other rapid tests employing these technologies are also under discussion.
